A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas
The purpose of this study is to test the safety and test any side effects, good or bad, that ribociclib (the study drug) has when used in combination with doxorubicin on participants with advanced soft tissue sarcoma.
Soft tissue sarcoma
15 years or older with metastatic or unresectable soft tissue sarcoma.
Further tests, procedures, and review of medical history will be done to confirm eligibility.
15 - 120
Healthy Volunteers Needed
Duration of Participation
The study drug and doxorubicin for up to 4 months and then the study drug by itself for as long as you are seeing benefit.
Knight Clinical Trials Office
Oregon Health & Science University